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Abstract
Post-operative nausea and vomiting (PONV) is defined as the occurrence of nausea,
vomiting or retching after a surgical procedure either in post anesthesia care unit or
within 24 hours after surgery. Post-operative nausea and vomiting , the second leading
problem faced in the post anesthesia care unit, can affect 30 -80% of surgical patients
based on patient-specific and anesthetic specific risk factors. There are several
medications used routinely to prevent and/ or reduce the incidence of PONV. The
purpose of this systematic review was to investigate the efficacy of propofol compared to
midazolam on reducing the incidence of PONV in the adult population after general
anesthesia. A database search was conducted using inclusion and exclusion criteria to
select pertinent research articles from 2009 to 2019. The PRISMA framework was
utilized to guide the review and assist with article selection. Then, the CASP checklist
guided the appraisal of each article included in the review. Data collection tables were
created, and a cross-study analysis was conducted to explore the results of each article.
Studies showed that both propofol and midazolam have anti-emetic properties
even though the mechanisms of action are not truly understood. Overall, propofol and
midazolam alone or in combination with other anti-emetics showed significant reduction
in PONV and rescue anti-emetic requirement. By incorporating the use of propofol or
midazolam into the anesthetic plan, anesthesia providers will be able reduce the
incidence of PONV and decrease the associated adverse outcomes.
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Propofol Versus Midazolam on Reducing the Incidence of Post-Operative Nausea and
Vomiting: A Systematic Review
Background/Statement of the Problem
Post-operative nausea and vomiting (PONV) is defined as the occurrence of
nausea, vomiting or retching after a surgical procedure either in the post-anesthesia care
unit (PACU) or within 24 hours after surgery (Horn, Wallisch, Homantics & Williams,
2013). PONV, the second leading problem faced in the PACU, can affect 30 -80% of
surgical patients based on patient-specific and anesthetic specific risk factors (Nagelhout
& Elisha, 2018). The risk factors that increase the incidence of PONV include female
gender, non-smoker, history of PONV, history of motion sickness, and age less than 50
years old. Anesthetic related factors include use of volatile gases, use of nitrous oxide,
duration of the surgery, and post-operative opioid use. According to Shaikh, Nagarekha,
Hegade & Marutheesh (2016), the type and length of surgery contributes to the risk as
well. The Society for Ambulatory Anesthesia (SAMBA), a multidisciplinary panel of
professionals, have implemented evidence-based guidelines and recommendations for use
of antiemetic prophylaxis and treatment for post-operative nausea and vomiting
(Nagelhout & Elisha, 2018). The guidelines identify risk factors, suggest strategies for
reducing PONV, identify effective therapies for prophylactically treating PONV
(monotherapy and multimodal), and recommend treatment for active PONV (Gan et al.,
2007). SAMBA further implemented an algorithm for the management PONV for atrisk individuals (Gan et al., 2007).
Post-operative nausea and vomiting (PONV) contributes to unfavorable
consequences like delayed recovery, aspiration, hospital admission or increased length of
stay, wound dehiscence and dehydration (Shaikh et al., 2016). For many decades, PONV
has been a problem for surgical patients due to its complex mechanism (Gibbison &
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Spencer, 2009). Extensive research has been conducted involving the effects of general
anesthesia on the incidence of post-operative nausea and vomiting. Prevention and
treatment of PONV involves a multimodal approach (Nagelhout, 2018).
Propofol, a short acting intravenous anesthetic, decreases the level of
consciousness and results in lack of memory of medical events. This medication has
proven to decrease the incidence of PONV in surgical patients receiving general
anesthesia. General anesthesia can be delivered via total intravenous anesthesia, using
volatile inhalation agents or a combination of both (Nagelhout & Elisha, 2018). The
largest challenge with general anesthesia is determining the best anesthetic plan for each
patient to reduce or prevent post-operative nausea and vomiting.
Midazolam, a benzodiazepine, is commonly used in anesthesia as a sedative,
anxiolytic, amnestic, and hypnotic drug (Nagelhout, 2018). According to Samimi Sade,
Davari Tanha & Sadeghi (2010), the anti-emetic properties of midazolam are not
completely understood but presumed to act at the chemoreceptor trigger zone (CRTZ).
The purpose of this systematic review was to investigate the efficacy of propofol
compared to midazolam on reducing the incidence of post-operative nausea and vomiting
in the adult population after general anesthesia.
Next, the literature review will be discussed.
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Literature Review
A review of literature was performed to investigate the efficacy of propofol
compared to midazolam at reducing the incidence of post-operative nausea and vomiting
in the adult population after general anesthesia. Research articles were obtained by
conducting a through database search on CINAHL, Medline, PubMed, and Google
Scholar. The search terms included general anesthesia, general anesthesia side effects,
post-operative nausea and vomiting, propofol, midazolam, PONV prevention,
prophylaxis treatment of post-operative nausea and vomiting, and anti-emetics. Random
control trials, meta-analyses, and prospective cohort studies from 2009 to 2019 were
included in the literature review.
Post-operative Nausea and Vomiting
Post-operative nausea and vomiting is defined as the occurrence of nausea,
vomiting or retching after a surgical procedure either in PACU or within 24 hours after
surgery (Horn, Wallisch, Homantics & Williams, 2014). PONV, the second leading
problem faced in the post-anesthesia care unit, can affect 30 -80% of surgical patients
based on patient-specific and anesthetic specific risk factors (Abdelhamid &
Kamel,2014). According to Horn et al. (2014), patients reported that PONV is the most
distressing adverse effect of anesthesia. The “vomiting center” (VC) in the medulla
oblongata is comprised of the reticular formation, a network of nuclei clusters and the
chemoreceptor trigger zone (CTZ) (Hall, 2011). The VC connects to the nucleus tractus
solitarius (NTS) that receives input from cardiovascular, respiratory, genital, and
digestive organs (Becker, 2010). The VC is activated by receiving many signals from
sensory nerves in the gastrointestinal tract (peripheral pathways), the CTZ, cerebral
cortex, and vestibular system (Moon, 2014). Stimulation to the forebrain pathway causes
nausea and stimulation of the hindbrain pathway results in coordinated parasympathetic
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and efferent nerve responses to produce vomiting (Moon, 2014). The CTZ consists of
receptors for dopamine, serotonin, acetylcholine, opioids, and substance P The zone is
located outside of the blood brain barrier, therefore, this area of the brain is susceptible to
stimulation from medications, toxins, and metabolites triggering vomiting (Becker,
2010).
The American Society of Anesthesiologists (ASA) created a classification system
to access a patient’s physical status prior to surgery (Abouleish, Leib, & Cohen, 2015).
There are six categories ranging from a healthy individual without systemic disease to an
individual that is declared brain-dead and/ or an organ donation candidate. Class I
represents a healthy individual with no past medical history and class II involves some
type of past medical history, prescribed medication or controlled systemic disease
process.
The study by Joe, Lee, Kim, Chang, Jeong, Jeong, & Park (2016) consisted of 72
adult women with an ASA I or II that were randomly divided into the sevoflurane
(volatile anesthetic gas) group or total intravenous anesthesia group using propofol. A
nausea severity scale was used for evaluation purposes. The collected data included the
incidence of post-operative nausea and vomiting, nausea, and vomiting in early (0-6
hours), late (6-24 hours), and overall (0-24 hours) and pain scores.
The study showed the use of both intravenous propofol and a rescue antiemetic, ramosetron, a serotonin type 3 receptor antagonist (5-HT₃), had significant
reduction on the incidence of PONV compared to the sevoflurane (volatile anesthetic
gas) group. The incidence of PONV in the early post-operative period in the total
intravenous anesthesia group was 4 (11.1%) compared to the Sevoflurane group which
was 20 (55.6%) with a P< 0.001 (Joe et al., 2016). In the late period (6-24 hours), PONV
in the intravenous propofol group was 6 (16.7%) compared to 11 (30.6%) and the overall
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incidence of PONV was 7 (19.4%) compared to 22 (61.1%) with P=0.001 (P< 0.05
considered statistically significant) (Joe et al., 2016). The study suggested TIVA with
propofol effectively reduces the incidence of PONV compared to using volatile gases
such as sevoflurane.
Risk Factors for Post-operative Nausea and Vomiting
The patient-related risk factors of PONV include female gender, non-smoker,
history of PONV, history of motion sickness, and age less than 50 years old. Anesthetic
related factors include use of volatile gases, use of nitrous oxide, duration and type of the
surgery, and post-operative opioid use (Moon,2014). Risk of PONV may be quantified
by using the Apfel scoring system consisting of four factors. The Apfel score ranges
from 0-4, predicting the percentage of PONV risk in the first 24 hours post-operatively.
Öbrink, Jidenstål, Oddby & Jakobsson (2015) suggested that providing opioid
free anesthesia is effective at reducing the incidence of post-operative nausea (68% vs.
27%) and vomiting ( 32% vs 8%). Horn et al. (2014) suggested that increased duration of
surgery, tissue trauma, and inflammation contribute to the incidence of PONV.
According to Pierre & Whelan (2013), dose dependent opioid use intraoperatively
and post-operatively increased the risk of PONV. “Opioids reduce muscle tone and
peristaltic activity, thereby delaying gastric emptying, inducing distention, and triggering
the vomiting reflex” (Pierre & Whelan, 2013, pg. 29). The most common procedures that
increase the incidence of PONV include abdominal, orthopedic, gynecologic, and middle
ear surgeries (Arcangelo & Peterson, 2013). PONV contributes to unfavorable
consequences like delayed recovery, aspiration, hospital admission or increased length of
stay, wound dehiscence and dehydration (Shaikh et al., 2016).
In 2015, the study by Naghibi, Kashefi, Azarnoush & Zabihi consisted of 104
adult subjects with an ASA status of I or II that underwent lower abdominal surgery
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electively. The subjects were randomly divided into one of the four groups, the control,
20mg propofol, 30mg propofol, or the 10mg metoclopramide group (Naghibi et al.,
2015). Naghibi et al. (2015) revealed in the first six hours following surgery both
propofol groups showed decreased incidence of PONV with 23.08% and 15.38% in
group 1 and 2 respectively developing PONV. The study further suggested that the
propofol 30 mg group and the metoclopramide 10 mg group were comparable at
decreasing the incidence of PONV compared to the control group developing
PONV (Naghibi et al., 2015).
Obtaining a complete pre-anesthesia assessment is crucial to prevent and
reduce the incidence of post-operative nausea and vomiting (Arcangelo & Peterson,
2013). Reviewing the patient’s chart and interviewing the patient on day of surgery can
potentially alert the advanced practice provider to any risk factors for developing PONV.
Pharmacological Therapies
The main objective is prevention and reduction of the incidence of PONV to
improve patient satisfaction and potentially reduce health care costs related to untoward
effects of anesthesia. Anti-emetic preventative medications consist of serotonin
antagonists, antihistamines-anticholinergics, corticosteroids, phenothiazines,
butyrophenones, benzodiazepines, propofol, and the more recent neurokinin 1
antagonists (Shaikh et al., 2016). The most common anti-emetics used in the operative
setting consist of serotonin antagonists (5HT₃), corticosteroids, dopamine receptor
antagonists, antihistamine-anticholinergics, and more recently propofol and benzodiazepines (Moon, 2014). According to Shaikh et al. (2016), PONV is a multifactorial
adverse effect of general anesthesia and effective treatment involves a multimodal
approach.

7

Serotonin antagonists.
Serotonin receptor antagonists (5HT₃) are used as preventative and rescue
treatment for PONV in the post-operative acute care unit (PACU) (Horn et al., 2014).
This class of medication involves antagonism of both peripheral and central afferent
receptors that cause nausea and vomiting (Horn et al., 2014). Ondansetron (Zofran) is the
anti-emetic commonly used in the peri-operative setting. Typical dosing of Zofran
consists of 4mg intravenous dose given either after induction of anesthesia or towards the
end of the surgery. The adverse effects include headache, abdominal pain, malaise,
increased liver enzymes, and potential prolongation of the QT interval (Arcangelo &
Peterson, 2013).
Corticosteroids.
Corticosteroids or steroid hormones are produced in the adrenal cortex and are
involved in several processes throughout the body such as stress response, inflammation,
immune response, metabolism of carbohydrates and synthesis of proteins (Nagelhout &
Elisha, 2018). Steroid hormones are classified as glucocorticoids or mineralocorticoids.
Glucocorticoids are anti-inflammatory, immunosuppressive, vasoconstrictive, and
proliferative and mineralocorticoids regulate electrolyte and fluid balance (Nagelhout &
Elisha, 2018). Dexamethasone, the commonly used synthetic corticosteroid is
almost like pure glucocorticoids found in the adrenal cortex (Ho, Wu, Ho, & Wang,
2011). In the intra-operative setting, dexamethasone is used in conjunction with
ondansetron to prevent PONV after general anesthesia however, the mechanism of action
for dexamethasone remains unclear (Ho et al., 2011). Even though corticosteroids have
adverse effects with long term use, a single anti-emetic dose is relatively safe though
contraindicated in diabetics unless benefit outweighs the risk (Nagelhout & Elisha, 2018).
The randomized control study by Heidari, Talakoub & Yaraghi (2012), consisted
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of 66 subjects undergoing elective middle ear surgery. The study compared the effects
of midazolam and midazolam-dexamethasone on the prevention of PONV. The subjects
were divided into two groups: midazolam (M) group that received 0.075mg/kg and the
midazolam/ dexamethasone (M+D) group that received 0.075mg/kg of midazolam plus
0.05 mg/kg of dexamethasone after induction. Nausea severity was measured in PACU
at time intervals of 6, 12, and 24 hours after surgery using the visual analog scale (0-10).
The rescue anti-emetic used was metoclopramide 0.1 mg/kg if the VAS score was above
3 or vomiting was present. This data was collected along with the length of stay in
PACU. The study revealed less vomiting frequency in the combination group in PACU
(0 ± 0), 6-12 h (0.3± 0.8), and 12-24h (0.03 ± 0.17) and reduced rescue anti-emetic
requirements in the first 24 hours post-surgery in the combination group (P < 0.05). The
study suggested the use of both midazolam and dexamethasone to effectively prevent
PONV compared to midazolam alone.
Antihistamines-anticholinergics.
Antihistamines-anticholinergics are two classes of medication that include agents
used for mild nausea and motion sickness however, scopolamine has been used
cautiously in the operative setting due to post-operative delirium in the older population.
“Scopolamine is a competitive inhibitor at postganglionic muscarinic receptors in the
parasympathetic nervous system and acts directly on the central nervous system by
antagonizing cholinergic transmission in the vestibular nuclei” (Horn et al., 2014, pg. 8).
The mechanism of action involves the visceral sensory pathways that contribute to nausea
and vomiting (Arcangelo & Peterson, 2013). The scopolamine patch is used for surgical
patients with a history of severe motion sickness (Horn et al., 2014).
Dopamine antagonists.
According to Moon (2014), dopamine receptors, mainly D₂ and D₃, are shown to
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induce nausea and vomiting by reducing cAMP in the vomiting center of the brain
(Moon, 2014). Of the dopamine antagonists, metoclopramide (Reglan) and droperidol
are the common medications used as part of a multimodal approach in preventing and
treating post-operative nausea and vomiting (Nagelhout & Elisha, 2018). Droperidol is a
selective dopamine D₂ receptor antagonist. Horn et al. (2014) suggested that droperidol
is as effective as dexamethasone or ondansetron at preventing PONV. The most common
side effects include restlessness, minimal effect on sedation, QT prolongation, and
ventricular arrhythmias (Horn et al., 2014). According to Gan (2004), cases of QT
prolongation and/or torsade de pointes have been reported, therefore the FDA suggested
droperidol be used with caution and reserved for use when other anti-emetics fail (Gan,
2004 ). FDA further suggested the use of droperidol was contraindicated for patients
with known or suspected QT prolongation, including patients with congenital long QT
syndrome (FDA, 2020) . Metoclopramide, a potent D₂ receptor antagonist, also blocks
H₁
and 5-HT₃ receptors that enhances gastrointestinal motility, leading to an anti-emetic
effect (Moon, 2014).
Honarmand, Safavi, Khalili, & Mohammadnejad (2012) conducted a randomized,
double-blind, placebo-controlled study consisting of 80 adult subjects scheduled for
middle ear surgery under general anesthesia. The subjects were randomly allocated into
one of four groups: control (C), midazolam (M), haloperidol (H), or haloperidol plus
midazolam (HM) group. Subjects were evaluated by collecting data on incidence of
PONV, post-operative pain, extra- pyramidal side effects, arrhythmias, and headache at
0-2 hours and 2-24 hours post anesthesia (Honarmand et al., 2012). The authors revealed
the incidence of PONV in the H group was 12 (60%), M group 13 (65%), HM group 5
(25%) and C group 20 (100%) (Honarmand et al., 2012). The HM group also had the
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highest incidence of complete response with 70% of the group denying PONV
(Honarmand et al., 2012). The study suggested that midazolam in combination
with haloperidol decreases the incidence of PONV in the first 24 hours post anesthesia
(Honarnamd et al., 2012).
Propofol.
Propofol, a lipophilic, sedative hypnotic medication, is commonly utilized for
induction and maintenance of anesthesia. Due to the quick onset and short duration of
action, propofol can be utilized for procedural sedation in the intensive care unit or the
endoscopy department (Nagelhout & Elisha, 2018). The anti-emetic mechanism of
action for propofol still remains unclear however several mechanisms have been
proposed. The proposals suggest that propofol directly depresses the vagal nuclei, the
chemoreceptor trigger zone, and other areas contributing to nausea and vomiting
(Miller & Gan, 2015).
The study by Kim, Park, Kang, Choi, and Lee (2014), was a prospective, doubleblind, randomized control trial of 107 women scheduled for a laparoscopy-assisted
vaginal hysterectomy. The authors evaluated the anti-emetic efficacy of propofol when
administered at the conclusion of surgery (Kim et al., 2014). The women were divided
into three randomized groups: the control group, the 0.5 mg/kg propofol group, and the
1mg/kg propofol group. Data was collected on pain level, nausea, time spent in the postoperative unit, and use of rescue anti-emetics (Kim et al., 2014). The authors revealed
that the incidence of nausea was significantly lower in the two propofol groups compared
to the control group (12.1%, 14.7%, and 40% respectively). The results showed that a
low dose of propofol can reduce the occurrence of PONV in the post anesthesia care unit
(Kim et al., 2014).
Another study consisted of 120 subjects divided into three groups: propofol
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group, dexamethasone group, and control group (Celik et al., 2015). The data collected
consisted of the incidence of nausea, vomiting, and rescue anti-emetic requirement. Data
was recorded at the following intervals: 0-6 hours, 6-12 hours, and 12-24 hours post
anesthesia using a four-point post-operative nausea and vomiting scale (Celik et al.,
2015). The authors stated that the anti-emetic effects of propofol and dexamethasone
were equivalent for the prevention of PONV in the first 24 hours post anesthesia.
The study by Yimer, Ayalew, Abdisa & Aregawi (2017), was a prospective cohort study
of 72 adults scheduled for open abdominal surgery. The authors evaluated the efficacy of
sub hypnotic dose of propofol on the incidence and severity of PONV. The subjects were
evenly allocated into two groups: the propofol and non-propofol group. Data collection
included the incidence of PONV at intervals of 0-6h, 6-12h, 12-24h, hemodynamic
parameters, respiratory depression, severity of nausea and any side effects. (Yimer et al.,
2017). The severity of nausea was assessed utilizing a 11-point numerical scoring
system and the Bellville scoring tool to assess nausea and vomiting. The authors
revealed that propofol at sub-hypnotic doses reduce the incidence of PONV in patients
undergoing abdominal surgery electively and emergently. According to Yimer et al.,
(2017), the need for rescue anti-emetics was decreased in the propofol group compared to
the non-propofol group.
Midazolam.
Midazolam, a benzodiazepine, is commonly used pre-operatively because of the
anxiolytic and amnestic properties of the medication. The proposed anti-emetic
mechanism of action of midazolam involves the reduction of dopamine input at the CTZ
and potentially decreasing adenosine reuptake (Nagelhout & Elisha, 2018). According to
the meta-analysis by Grant et al. (2016) the use of midazolam significantly reduced
rescue antiemetic requirement for the prevention of post-operative nausea and vomiting
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in the adult population. The authors further suggested that the use of midazolam alone or
in combination with other antiemetics showed significant reduction in the incidence of
PONV, nausea, and vomiting within the first 24 hours post anesthesia (Grant et al.,
2016).
Another study consisting of 54 subjects scheduled for intragastric balloon
insertion was divided into two groups: ondansetron and ondansetron/ midazolam group
(Abdelhamid & Kamel, 2014). Subjects were evaluated by collecting data on the
incidence of nausea and vomiting, degree of sedation, nausea and vomiting score and
incidence of adverse effects in the first 24 hours post anesthesia (Abdelhamid & Kamel,
2014). The authors revealed the incidence of nausea and vomiting was 17 (66% of
subjects) in the ondansetron group and 9 (34.5% of subjects) in the ondansetron/
midazolam group. The authors further suggested the use of midazolam as an adjunct
provides a significant reduction in PONV (Abdelhamid & Kamel, 2014).
Next, the theoretical framework will be discussed.
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Theoretical Framework
In 2009, the Preferred Reporting Items of Systematic reviews and Meta-Analyses
(PRISMA) statement or framework was developed to guide systematic review research.
This framework was used to guide this major project. The PRISMA framework consists
of a four-phase flow diagram and a 27- item checklist (Liberati, Altman, Tetzlaff,
Mulrow, Gøtzsche et al., 2009). The flow diagram (See Appendix A) helps
identify and organize research articles obtained for analysis based on inclusion and
exclusion criteria (Liberati et al., 2009). The four phases are identification, screening,
eligibility, and included. The checklist (See Appendix B) helps to analyze, organize, and
develop a comprehensive selection of research articles for the systematic review (Liberati
et al., 2009). The checklist consists of six main sections: title, abstract, introduction,
methods, results, discussion, and funding. There are 27 subsections included in this
organizational checklist.
Post-operative nausea and vomiting has been extensively researched by
anesthesiologists, certified registered nurse anesthetists, and a combination of both
over the past ten years (Gibbison & Spencer, 2009). The pharmaceuticals used to
manage PONV have changed over the years from individual medications to a multimodal approach that is used currently. Conducting a thorough and valid systematic
review is the goal of this major project. PRISMA provides a framework to accomplish
this goal.
Next, the methods will be discussed.
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Method
Purpose
The purpose of this systematic review is to investigate the efficacy of propofol
compared to midazolam on reducing the incidence of PONV in the adult population after
general anesthesia.
Inclusion/ Exclusion Criteria
The inclusion criteria consisted of randomized control trials, meta-analyses, and
cohort studies conducted within the last 10 years; adult subjects having elective surgery
with general anesthesia; ASA I - II status; studies containing data for incidence of PONV,
and articles in English. The PRISMA flowchart was utilized to identify and organize the
articles based on this criterion.
The exclusion criteria consisted of articles published over 10 years ago, subjects
under the age of 18 years old, subjects with history of drug or alcohol abuse, history of
renal, kidney or liver disease and studies without data on the incidence of PONV after
general anesthesia. The PRISMA flowchart was utilized to identify and organize the
articles based on this criterion.
Search Strategy
Research articles were obtained by conducting a through database search on
CINAHL, Medline, PubMed, and Google Scholar. The search terms included postoperative nausea and vomiting, general anesthesia side effects, propofol, midazolam,
PONV prevention, prophylaxis treatment of PONV, and anti-emetics.
Data Collection
After article selection, two data collection tables were created for each article
included in the systematic review. Table 1 includes the demographics of each study
including citation, aim, design, sample, site, method, procedures, and results (See
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Appendix C).
Table 1
Demographics of Study
Citation
Aim

Design

Sample

Method

Procedures

Medication Used/ Results

________________________________________________________________________
Table 2 contains the results of each study including the citation, incidence of nausea
and vomiting, use of other anti-emetics, opioid use, induction/ maintenance medications,
and limitations (See Appendix D).
Table 2
Study Results
Citation
N/V

Rescue anti-emetics

Induction/Maintenance Meds

Side Effects

Limitations

________________________________________________________________________

Data Analysis
The Critical Appraisal Skills Programme (CASP) was utilized to evaluate the
validity of the research articles selected for this systematic review (Critical Appraisal
Skills Programme, 2018). The CASP checklist (See Appendix E) consists of 10-questions
to confirm that the selected studies correlate to the purpose of the systematic review. The
checklist includes the following three sections: validity, results, and applicability to
practice (Critical Appraisal Skills Programme, 2018). Once data collection and the
CASP checklist was completed (See Appendix F), a cross-study analysis tables was
created to analyze incidence of nausea and vomiting, use of other rescue anti-emetics,
adverse effects, and opioid use (Table 3, See Appendix G).
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Table 3
Cross-Study Analysis
Study #

N/ V

Rescue Anti-Emetics

Adverse Effects

Opioid Use

________________________________________________________________________
Next, the results will be discussed.
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Results
After a comprehensive database search 72 articles were retrieved for screening. The
PRISMA flowchart (Appendix A) was used to guide, organize, eliminate duplicates, and
further screen the appropriate articles based on inclusion and exclusion criteria. After
duplicates were removed, 31 articles remained, 15 full text articles were then screened,
and 7 more were then excluded based on lack of appropriate data. The eight remaining
articles were included in the systematic review consisting of seven randomized control
trials and one prospective cohort study. The results presented here were extracted from
the data collection tables (Appendix D 1-8), and cross-study analysis table (Appendix G)
created by the author.
The study by Abdelhamid et al. (2014) was a prospective randomized control trial
consisting of 54 subjects aged 18-40 with an ASA physical status of I or II presenting for
intragastric balloon insertion surgery. The incidence of PONV, nausea/ vomiting score,
and degree of sedation were collected immediately in PACU, then at intervals of 30- and
60-minutes post-anesthesia. Incidence of adverse effects were collected during the first
24 hours post-anesthesia. The subjects were randomly allocated into two groups:
ondansetron group (8mg) and the ondansetron / midazolam group (8mg/ 0.075mcg/kg).
Anesthesia induction was universal in all cases using fentanyl, propofol, cisatracurium
and maintenance consisted of propofol infusion. The data was analyzed using SPSS 18
software, Kolmogorov-Smirnov test, t-test, Chi-square test, Monte Carlo test, Fisher’s
exact test and p value of < 0.05 was considered significant. The authors revealed the
incidence of PONV in first 24 hours in ondansetron only group was 14 (56%) compared
to 10 (34.5%) in the ondansetron/ midazolam group (P=0.113). According to
Abdelhamid et al. (2014) there was not significant reduction in incidence of PONV
(P=0.113), however there was a significant difference in nausea/ vomiting scores
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(P=0.015) in the first 24-hour period. The study revealed in the ondansetron group (G1)
11 (44%) without nausea or vomiting, 0 with nausea only, 4 (16%) with vomiting only,
and 10 (40%) with both nausea and vomiting. They further revealed in the ondansetron/
midazolam group (G2) 19 (65.5%) without nausea or vomiting, 3 (10.3%) with nausea
only, 0 with vomiting only, and 7 (24.1%) with both nausea and vomiting. Regarding
sedation, 20 (80%) of ondansetron group were mildly sedated immediately post
compared to 17 (58.6%) in group 2 (P=0.018). Then 30 minutes after surgery zero were
mildly sedated in ondansetron group compared to 7 (24.1%) in group 2 (P=0.012). The
limitations of this study included lack of control group, no other side effect data was
collected other than sedation, uneven subjects per group, and no mention of rescue antiemetic requirement. The authors suggested that midazolam/ ondansetron significantly
reduced the severity of PONV according to nausea/ vomiting scores but not the overall
incidence of PONV.
The randomized, double blind, placebo-controlled study by Celik et al. (2014)
consisted of 120 adult subjects, both male and female with ASA status I or II presenting
for laparoscopic cholecystectomy. The purpose of the study was to evaluate the efficacy
of sub-hypnotic dose propofol with dexamethasone on the incidence of PONV. The
subjects were randomly assigned to one of three groups: propofol, dexamethasone, or the
control group (n=40). The data collected included incidence of PONV, rescue antiemetic requirement, and rescue analgesic needed in the first 24 hours post-surgery.
Nausea, vomiting and anti-emetic usage was recorded at intervals of 0-6h, 6-12h, and 1224h. The visual analog scale and PONV four-point scale were used to quantify nausea
and severity of vomiting. Induction of anesthesia was universal for all cases using
thiopental sodium 5mg/kg, fentanyl 1mcg/kg, and rocuronium for paralytic. Anesthesia
was maintained with 1-2.5% sevoflurane, 50% oxygen and fentanyl 1mcg/kg/h in the
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dexamethasone group(Group D) and propofol infusion 1mg/kg/h in propofol group
(Group P). The data was analyzed using the program of SPSS 20, ANOVA, Chi-test and
a p value of < 0.05 was considered significant. The study revealed significant reduction in
PONV between the control group and the group P and group D at all three-time intervals
(P< 0.05). At the 0-6h interval 65% of the control group experienced PONV compared to
30% in the other two groups (P< 0.05). At the 6-12h interval there was a significant
reduction among the groups, 52.5% of control group, 25 % of propofol group, 20% of
dexamethasone group experienced PONV (P < 0.05 when compared to control group).
The study also showed significant difference in number of subjects requiring rescue antiemetics in the control group 13 (32.5%) compared to the propofol group 4 (10%) and the
dexamethasone group 4 (10%) (P=0.01 for both). There was no significant difference in
analgesic requirements between the propofol and dexamethasone groups, however there
was a significant difference between the control and dexamethasone groups (P=0.04).
The next randomized control study by Heidari et al. (2012) consisted of 66
subjects aged 18-65 with an ASA status of I or II presenting for elective middle ear
surgery. The subjects weighed less than 100 kg without history of motion sickness or
PONV and denied hypersensitivity to midazolam or dexamethasone. The aim of this
study was to compare the efficacy of midazolam and midazolam plus dexamethasone on
the incidence of PONV. The subjects were randomly divided into two groups: the
midazolam group (0.075 mg/kg) and the midazolam (0.075 mg/kg) plus dexamethasone
(0.05 mg/kg) group. Induction and maintenance of anesthesia were standardized for all
subjects. Data collection consisted of the incidence of PONV, severity of nausea/
vomiting measured via VAS (0-10) in PACU, 0-6h, 6-12h, and 12-24h intervals and
rescue anti-emetic requirements. The data was analyzed with a Chi-square, t-test, and p
value < 0.05 was considered significant. The authors revealed a mean nausea score of

20

1.39 ±3.19 in the midazolam group (P=0.049) and 0.42 ± 1.71 in the midazolam/
dexamethasone group (P=0.049) and rescue anti-emetic requirements were higher in the
midazolam group (12.9 ± 23.44 mg) compared to the combination group (6.48 ±9.54mg)
(P <0.05 for both). The mean vomiting frequency in the PACU (P=0.039), at intervals of
6-12h (P=0.04) and 12-24h (P=0.047) were significantly different between the groups.
The authors revealed that midazolam does have some anti-emetic properties however in
combination with dexamethasone the effects were superior to single medication therapy.
The limitations of this study included lack of control group and small sample size
therefore, further studies would be needed to better compare these medications on
preventing and / or reducing the incidence of PONV.
The randomized, double-blind, placebo-controlled study by Honarmand et al.
(2012) consisted of 80 subjects aged 18-60 with an ASA status of I or II presenting for
middle ear surgery under general anesthesia. The subjects were randomly and evenly
allocated into one of four groups (n=20). The haloperidol group (2mg), midazolam group
(2mg), haloperidol/ midazolam group (2mg of each), or the control group (saline). Both
induction and maintenance of anesthesia were standardized in all cases. The data
collection consisted of incidence of PONV, complete response to treatment, pain,
occurrence of side effects (arrhythmias, headache), and rescue anti-emetic requirement
at three intervals: 0-2h, 2-24h, 0-24h. Tests used to analyze data were ANOVA, Pearson
Chi-square test, Fisher’s exact test, Mann-Whitney U-test, SPSS 16.0 software and p
value of <0.05 was considered significant. The authors revealed comparable
complete response between the haloperidol and control group with 20% of the group
without PONV. The midazolam group had a 45% complete response (P< 0.05) and the
haloperidol/ midazolam had a 70% complete response (P<0.05). Further comparison
revealed that haloperidol/midazolam was more effective than midazolam only at the 2-
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24h and 0-24h intervals (P< 0.05 for both). According to Honarmand et al. (2012), the
midazolam and haloperidol group rescue anti-emetic requirements were comparable
however the haloperidol/midazolam group requirement (0.5± 1.5mg) was significantly
less than the other three groups [2.0- 6.5±4.1- 4.6mg (p< 0.05)]. The study further
revealed no significant differences in side effects, sedation, VAS score, or post-operative
analgesic requirement. The limitations of the study included small sample size and
severity of nausea was not evaluated.
Next, the prospective randomized study by Joe et al. (2016) consisted of 72
females aged 20-60 with an ASA status of I or II presenting for thyroidectomy under
general anesthesia. The purpose of study was to evaluate the efficacy of combined
ramosetron and total intravenous anesthesia (TIVA) on the incidence of PONV. The
subjects were allocated into either the sevoflurane group or the TIVA with ramosetron
group (n=36). Data collection included incidence and severity of PONV and rescue antiemetic requirements for each group at intervals of 0-6h, 6-24h, and 0-24h post-surgery.
The data was analyzed using SPSS 17.0 program, Student’s t-test, x²-test, and p values of
< 0.05 were considered significant. The study revealed a significant reduction of PONV
and reduced rescue anti-emetic requirements in the TIVA group at all intervals compared
to the other group. In the first 24h, 7 (19.4%) in TIVA group and 22 (61.1%) in
sevoflurane group experienced PONV (P=0.001), and 4 (11.1%) and 15 (41.7%) needed
rescue anti-emetic respectively (P=0.007). Therefore, the authors suggest the use of
TIVA over the use of volatile anesthetics at reducing the incidence of PONV. The
limitations of this study include lack of TIVA control group and small sample size.
The prospective, double-blind randomized control study by Kim et al. (2014)
consisted of 107 females with ASA status of I or II presenting for laparoscopy assisted
vaginal hysterectomy under general anesthesia. The aim of this study was to evaluate the
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antiemetic effect of varying doses of propofol given prior to end of surgery. The subjects
were allocated into 1 of 3 groups: the propofol 0.5 mg/kg group, propofol 1 mg/kg group
or the control saline group. Induction and maintenance of anesthesia were universal for
all cases and propofol or saline were given 15 minutes prior to end of case. Data
collection included incidence of PONV and nausea/vomiting severity at 0-2h, 2-24h, and
24-48h post-surgery. The data was analyzed using SPSS 18.0, Sigma Stat 12.0, Chisquare test, Fisher’s exact test, ANOVA, and a p value of <0.05 was considered
significant. The authors used the visual analog scale (0-10) to quantify nausea/
vomiting severity. The study revealed a significant reduction of PONV (P=0.007) and
less need for rescue anti-emetics (P=0.026) in both the propofol groups compared to the
control group. At the 0-2h interval, the incidence of PONV for the control group was 16
(P=0.007), propofol (0.5mg/kg) 4 (P=00.07), and propofol (1mg/kg) 5 (P=0.007). The
authors showed no significant difference between the propofol doses on the incidence of
PONV (4 and 5 respectively) and rescue anti-emetic requirement (1 and 2 respectively).
The authors further revealed prolonged emergence period in the propofol groups
compared to the control group (P=0.038 and P=0.006 respectively). The limitations of
this study includes relatively small sample size and no comparison between propofol and
other anti-emetics. According to Kim et al. (2014) even though propofol prolonged
emergence, it effectively reduced the incidence of PONV and rescue anti-emetic
requirements, therefore proving to be a positive adjunct to the anesthetic plan.
Another prospective, randomized, double-blind, placebo-controlled study by
Naghibi et al. (2015) consisted of 104 subjects aged 18-65 years with ASA status I or II
and BMI < 30 kg/m² presenting for elective lower abdominal surgery under general
anesthesia. The purpose of this study was to compare the effects of sub-hypnotic dose of
propofol with metoclopramide. The subjects were randomly assigned into 1 of 4 groups:
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propofol 20mg (G1), propofol 30mg (G2), metoclopramide 10mg (G3), or placebo saline
group (G4). Data collection consisted of incidence and severity of PONV, side effects of
anti-emetics, duration of surgery and recovery period recorded at 0-6h, 6-12h, and 12-24h
intervals. Induction and maintenance of anesthesia was universal in all cases and
baseline hemodynamic were also collected. The data was analyzed using SPSS 20
software, Student’s t-test, x²- test, ANOVA, and p value of <0.05 was considered
significant. The study revealed significant reduction in PONV in the propofol groups
compared to the control. The incidence of PONV 0-6h post-anesthesia was 6 (23.08%) in
G1 (P=0.005), 4 (15.38%) in G2 (P=0.016), 4 (15.38%) in G3 (P=0.016), and 8 (30.77%)
in G4 (P=0.005) (Kim et al., 2014). However, the propofol groups were comparable at
reducing PONV and the propofol 30 mg group was also comparable to the
metoclopramide group (P=0.016). There was less rescue anti-emetic requirement in both
propofol groups and metoclopramide group compared to the control group (P=0.042).
The authors revealed the mean dose of anti-emetic was comparable in both propofol
group (5.2±2.1 mg vs 5±0.9 mg) and metoclopramide group (6±1.8 mg). No side effects
were noted in the study and limitations of this study included small sample size and
subjects were followed for first 24 hours post-surgery.
Lastly a prospective cohort study by Yimer et al. (2017) consisted of 72 subjects
aged 18 or older with ASA status of I or II presenting for open abdominal surgery under
general anesthesia. The aim of this study was to assess the efficacy of sub-hypnotic dose
of propofol on the incidence of PONV. Data collection included the incidence of PONV
at intervals of 0-6h, 6-12h, 12-24h, hemodynamic parameters, respiratory depression,
severity of nausea and any side effects. Induction and maintenance of anesthesia were
universal for all cases. The data was analyzed using SPSS 20 software, Student’s t-test,
Fisher’s exact test, Shapiro-Wilk normality test, Mann-Whitney U test, Chi-square test,
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and p value <0.05 was considered significant. The authors revealed significant reduction
in PONV in the propofol group 11 (30.6%) in the first 6 hours compared to the control
group 24 (66.7%) (P=0.002), no significant differences in hemodynamic stability and
respiratory depression and noted more severe nausea in the control group. The study also
showed a significant reduction in rescue anti-emetic needed in the propofol group
compared to the control group [5 (13.9%) and 15 (41.7%) respectively, (P=0.009)]. The
limitations of this study included lack of group randomization; lack of anti-emetic used
after 6 hours post-surgery, and the subjects were followed for the first 24 hours postoperatively.
All eight research articles were analyzed using the CASP appraisal tool to
evaluate the validity of the research article and applicability to practice (Appendix F 1-8).
Seven of the eight articles had 9 out of 9 “yes” to the appraisal questions (Abdelhamid
et al. F-1,Celik et al., F-2, Heidari et al. F-3, Honarmand et al. F-4, Joe et al. F-5,Kim et
al. F-6, Naghibi et al. F-7). All seven articles were deemed valid for this systematic
review and the results were applicable to advanced nursing practice. The article by
Yimer et al. was a prospective cohort study and the subjects were not randomized but
were evenly allocated to either the propofol group or non-propofol group. Even though
the subjects were not randomized due to university rules, the nature and results of the
study showed enough validity to be included in this systematic review. Furthermore, the
results of this study were considered applicable to advanced nursing practice.
Next, summary and conclusions will be discussed.
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Summary and Conclusions
Post-operative nausea and vomiting (PONV) is defined as the occurrence of
nausea, vomiting or retching after a surgical procedure either in PACU or within 24 hours
after surgery (Horn, Wallisch, Homantics & Williams, 2014). PONV, the second leading
problem faced in the post-anesthesia care unit, can affect 30 -80% of surgical patients
based on patient-specific and anesthetic specific risk factors (Abdelhamid & Kamel,
2014). The patient-related risk factors of PONV include female gender, non-smoker,
history of PONV, history of motion sickness, and age less than 50 years old. Anesthetic
related factors include use of volatile gases, use of nitrous oxide, duration, and type of the
surgery, and post-operative opioid use (Moon,2014). PONV contributes to unfavorable
consequences like delayed recovery, pulmonary aspiration, unexpected hospital
admission or increased length of stay, delayed return to work, wound dehiscence and
dehydration. Furthermore, risk of PONV may be quantified by using scoring systems
such as the Apfel or the Visual Analog System (VAS). The Apfel scoring system
consists of four factors: gender, smoking status, history of motion sickness or PONV, and
use of post-operative opioids (Apfel et al. (2012). The Apfel score ranges from 0-4,
predicting the percentage of PONV risk in the first 24 hours post-operatively. The VAS
quantifies the severity of nausea / vomiting using a 0-10 scale.
A systematic review was conducted to investigate the efficacy of propofol
compared to midazolam on reducing the incidence of post-operative nausea and vomiting
in the adult population after general anesthesia. A review of literature was conducted
using the PRISMA flow chart (Appendix A) along with inclusion and exclusion criteria
set forth by the author. The data collected consisted of incidence of PONV, rescue antiemetic requirement, induction/ maintenance medication used, side effects, and
limitations (Appendix D 1-8). Eight articles were included in the systematic review ,
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seven random control trials and one prospective cohort study. Data collection tables were
created, CASP checklist (See Appendix E & F) was utilized to appraise each article
included in the review and a cross-study analysis table (See Appendix G) was created and
used to validate and compare the results of each article.
All the studies in this systematic review revealed that both propofol and
midazolam possesses anti-emetic properties. The review further suggests that both
medications significantly reduced the incidence of PONV (See Appendix D 1-8,
Appendix G) and seven studies revealed reduction in rescue anti-emetic requirements
with the use of either propofol or midazolam. However, four out of eight studies
revealed a multimodal approach was far superior at reducing the incidence of PONV
compared to single agent approach. The study by Heidari et al. (2012) showed
midazolam alone was effective at reducing the incidence of PONV however adding
dexamethasone had significant impact on reducing the incidence and reduced the antiemetic requirement by half. This systematic review supports the usage of these
medications in a multimodal approach and proven effective at reducing and preventing
PONV in the adult population after general anesthesia. Limitations to this study include
limited number of studies analyzed for the review; type of surgeries involved in the
studies because specific surgeries increase risk of PONV, one of the eight studies made
no mention of rescue anti-emetics, and small sample sizes of some studies included in the
systematic review.
In conclusion, both propofol and midazolam were shown to reduce the incidence
and severity of PONV in the adult population following general anesthesia. The
results of this systematic review can give certified registered nurse anesthetists (CRNA)
more options in the multimodal approach in the preventing and reducing the incidence of
PONV. Next, recommendations and implications for advanced nursing practice.
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Recommendations and Implications for Advanced Nursing Practice
The systematic review revealed information that can be valuable to the advanced
practice provider to incorporate into practice in order to reduce and/ or prevent the
incidence and/or severity of PONV in the adult population. PONV can affect 30-80% of
the surgical population, therefore, CRNA’s play a crucial role in planning and
implementing treatment to reduce and/ or prevent incidence of PONV. Advanced
practice providers incorporate evidence-based research, guidelines, and algorithms into
daily practice, therefore, information obtained from this systematic review would be
beneficial. Analyzing the risk factors can assist the CRNA at creating a more appropriate
plan of care to decrease the incidence of PONV. Implementing protocols to prophylactically treat PONV would reduce the adverse outcomes of anesthesia.
As CRNAs, a through preoperative assessment is key to determining which
patients are at increased risk of PONV by utilizing the assessment tools available (i.e.,
Apfel, Bellville). Discussing the potential risk with the patient can help to lessen anxiety
and potentially reduce the risk of PONV. After determining the patient’s risk of PONV,
the anesthesia provider can utilize the SAMBA algorithm (see Figure 1) to create an
appropriate plan of care (Hooper, 2015). As stated earlier, specific surgeries
pose an increased risk for PONV and those patients would benefit from a multimodal
approach for preventing and reducing PONV. CRNAs understand PONV is
multifactorial and most patients require a minimum of two anti-emetics, therefore, adding
a sub-hypnotic dose of propofol or pre-operative dose of midazolam proves safe and
effective in prophylactically treating PONV. With guidelines or protocols in place and
continuing education for anesthesia providers, prophylactically treating PONV shall
become an easier task. Increased awareness of the multiple drug options for management
shall help minimize the incidence of PONV, such as utilizing a preoperative sub-hypnotic
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midazolam dose not only for anxiolysis but also for the prevention of PONV. Even
though this review suggests effective reduction of PONV with the use of propofol or
midazolam alone or in combination with other anti-emetics, further research on this
topic is needed due to rapid pharmaceutical advancements.

Hooper, V. (2015). SAMBA Consensus Guidelines for the Management of Postoperative Nausea and Vomiting: An Executive
Summary for Perianesthesia Nurses. Journal of Perianesthesia Nursing, 30(5),377-382.
doi:https://doi.org/10.1016/j.jopan.2015.08.00

Figure 1 SAMBA Consensus Algorithm
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(n = 8)
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Appendix B
PRISMA Checklist
Section/topic

Reported
on page #

# Checklist item

TITLE
Title

1 Identify the report as a systematic review, meta-analysis, or both.

ABSTRACT
Structured summary

2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria,
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and
implications of key findings; systematic review registration number.

INTRODUCTION
Rationale

3 Describe the rationale for the review in the context of what is already known.

Objectives

4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons,
outcomes, and study design (PICOS).

METHODS
Protocol and registration

5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide
registration information including registration number.

Eligibility criteria

6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered,
language, publication status) used as criteria for eligibility, giving rationale.

Information sources

7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify
additional studies) in the search and date last searched.

Search

8 Present full electronic search strategy for at least one database, including any limits used, such that it could be
repeated.

Study selection

9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable,
included in the meta-analysis).

Data collection process

10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes
for obtaining and confirming data from investigators.

Data items

11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and
simplifications made.

Risk of bias in individual
studies

12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was
done at the study or outcome level), and how this information is to be used in any data synthesis.

Summary measures

13 State the principal summary measures (e.g., risk ratio, difference in means).

Synthesis of results

14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency
(e.g., I2) for each meta-analysis.

Page 1 of 2

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic
Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed100009
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PRISMA Checklist

Section/topic

# Checklist item

Risk of bias across studies

15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective
reporting within studies).

Additional analyses

16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating
which were pre-specified.

Reported
on page #

RESULTS
Study selection

17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at
each stage, ideally with a flow diagram.

Study characteristics

18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and
provide the citations.

Risk of bias within studies

19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).

Results of individual studies

20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.

Synthesis of results

21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.

Risk of bias across studies

22 Present results of any assessment of risk of bias across studies (see Item 15).

Additional analysis

23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).

DISCUSSION
Summary of evidence

24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to
key groups (e.g., healthcare providers, users, and policy makers).

Limitations

25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of
identified research, reporting bias).

Conclusions

26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.

FUNDING
Funding

27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the
systematic review.

Page
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From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred
Reporting
Items2for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097.
doi:10.1371/journal.pmed1000097
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Appendix C
Demographics of Study
C-1: Abdelhamid, S. & Kamel, M. (2014). A prospective controlled study to assess the antiemetic effect of midazolam following
intragastric balloon insertion. Journal of Anesthesiology Clinical Pharmacology, 30(3), 383-386. https://doi:10.4103/09709185.137272
Aim/ Purpose
To investigate
the efficacy of
ondansetron and
midazolam at
reducing the
incidence of
PONV after
intragastric
balloon
insertion

Design
Prospective
controlled trial,
patients randomly
allocated into two
groups
Ondansetron group
8 mg and
ondansetron/
midazolam group
8mg/ 0.075mcg/kg
(based on total
body weight)

Sample
54 subjects, aged
18-40, ASA
physical status I II, BMI 30-35
kg/m², presenting
for intragastric
balloon insertion
surgery

Methods
The incidence of
nausea and vomiting,
nausea/ vomiting
score, the degree of
sedation
(immediately, 30
minutes, and 60
minutes postanesthesia) incidence
of adverse effects
during the first 24
hours postoperatively
Anesthesia induction
and maintenance was
universal in all cases

Procedure
Elective
intragastric
balloon
insertion

Medication Used/ Results
Ondansetron,
ondansetron/midazolam
Significant reduction in the
severity of PONV in the
combination group compared
to ondansetron group.
Mild sedation occurred in early
post-operative period.
Nausea/ vomiting during 24h
post-operatively in group 1
was 56% (14 subjects) and
34.5% (10 subjects) in group 2
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C-2: Celik, M., Dostbil, A., Aksoy, M., Ince, I., Ahiskalioglu, A., Comez, M. & Fuat Erdem, A. (2014). Is infusion of sub hypnotic
propofol as effective as dexamethasone in prevention of post-operative nausea and vomiting related to laparoscopic cholecystectomy?
A randomized controlled trial. BioMed Research International, 2015, 1-5. https://dx.doi.org/10.1155/2015/349806
Aim/ Purpose
Evaluate the
efficacy of sub
hypnotic dose
of propofol
with
dexamethasone
on the
incidence of
PONV

Design
Randomized,
double blind,
placebo-controlled
trial
Subjects randomly
assigned to 1 of 3
groups: propofol
(1mg/kg/h),
dexamethasone
(8mg), or control
group (10 %
intralipid)

Sample
120 Subjects,
both male/
female, ASA
physical status I
or II presenting
for laparoscopic
cholecystectomy

Methods
Incidence of PONV, need
for rescue anti-emetic or
rescue analgesic recorded
in the first 24 hours post
anesthesia
Nausea, vomiting, antiemetic use was recorded at
3 periods: 0-6hours, 612hours, and 12-24 hours
Visual Analog Scale and
PONV four-point scale
Anesthesia induction and
maintenance was universal
in all cases

Procedure
Laparoscopic
cholecystectomy

Medication Used/ Results
Dexamethasone 8 mg
Propofol 1mg/kg/hour
Control 10% intralipids
15 minutes before skin
closure
Propofol and
dexamethasone were
comparable in 0-24-hour
post anesthesia period
Dexamethasone group
required less rescue antiemetic in 6-12 hours and
12- 24 hours post
anesthesia
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C-3: Heidari, S., Talakoub, R., & Yaraghi, Z. (2012). Comparing the preventive effect of midazolam and midazolamdexamethasone on postoperative nausea and vomiting in elective middle ear surgery. Advanced Biomedical Research, 1(9), 1-9.
http://doi:10.4103/2277-9175.96052
Aim/ Purpose
Design
Sample
Methods
Procedure Medication Used/ Results
To evaluate the
efficacy of
midazolam and
midazolam plus
dexamethasone
on PONV after
middle ear
surgery

Randomized,
double-blind,
controlled
study

66 ASA I or II, aged
18-65, weight <
100kg without
history of motion
sickness, pregnancy,
hypersensitivity to
either midazolam or
dexamethasone, and
PONV

Subjects randomly divided into 2 Elective
groups: midazolam (M)
middle ear
(0.075mg/kg) and midazolam
surgery
(0.075 mg/kg) plus
dexamethasone (M+D) (0.05
mg/kg)
Induction/ maintenance
standardized for all subjects,
universal monitoring for all
subjects
Severity of nausea /vomiting
measured by visual analog scale
in PACU, at 6,12, and 24h after
surgery, rescue anti-emetics and
PACU length of stay was also
recorded
Rescue anti-emetic was
metoclopramide 0.1 mg/kg

No significant
differences in age,
weight, and gender
between the groups
Mean nausea score
M group: 1.39 ±3.19
M+D group: 0.42 ±1.71
Mean Vomiting
frequency:
PACU: 0.9 ± 0.29 (M),
0 ±0 (M+D)
6-12h: 1.09 ±2.41 (M)
0.3 ± 0.8 (M+D)
12-24h: 0.42± 1.32 (M),
0.03 ± 0.17
Rescue Antiemetic
M: 12.9 ± 23.44
M+D: 6.48 ± 9.54
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C-4: Honarmand, A., Safavi, M., Khalili, G., & Mohammadnejad, F. (2012). Prophylactic administration of haloperidol plus
midazolam reduces postoperative nausea and vomiting better than using each drug alone in patients undergoing middle ear
surgery. Saudi Journal of Anesthesia, 6(2),145-151. https://doi:10.4103/1658-354X.97028
Aim/Purpose
Design
Sample
Methods
Procedures
Medication used/ Results
To evaluate the
anti-emetic
effects of the
combination of
intravenous
midazolam with
haloperidol on
PONV in
comparison to
each medication
alone

Randomized,
double-blind,
placebo-controlled
study (n=80)
4 Groups:
Group H: (n=20)
Haloperidol 2 mg IV
Group M: (n=20)
Midazolam 2 mg IV
Group HM: (n=20)
Haloperidol 2 mg IV
Midazolam 2 mg IV
Group C: (n=20)
Saline IV

80 ASA status
I or II, aged
18-60, undergoing surgery
with general
anesthesia

Induction/
maintenance of
anesthesia universal
Midazolam,
haloperidol or both
were given 30 min
before conclusion of
surgery
Data on incidence of
PONV, complete
response, pain,
occurrence of side
effects, arrhythmias,
rescue anti-emetics
and headache was
collected for 0-2h, 224h, & 0-24h, VAS
scoring system was
used

Middle ear
surgery

Group H:
Complete Response 4 (20%)
0-2h: 6 (30%)
2-24h: 6 (30%)
0-24h: 12 (60%)
Group M:
Complete Response 9 (45%)
0-2h: 9 (45%)
2-24h: 4 (20%)
0-24h: 13 (65%)
Group HM:
Complete Response 14
(70%)
0-2h: 3 (15%)
2-24h: 2 (10%)
0-24h: 5 (25%)
Group C:
Complete Response 4 (20%)
0-2h: 10 (50%)
2-24h: 10 (50%)
0-24h: 20 (100%)
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C-5: Joe, H. B., Lee, S. Y., Kim, J.-S., Chang, H. S., Jeong, Y., Jeong, H., & Park, S. Y. (2016). Effect of total intravenous anesthesia
and prophylactic ramosetron on postoperative nausea and vomiting after thyroidectomy: A prospective, randomized controlled study.
Journal of International Medical Research, 44(1), 81–88. https://doi.org/10.1177/0300060515607384
Aim/ Purpose
Design
Sample
Methods
Procedures
Medication Used/ Results
To evaluate the
efficacy of
combined
ramosetron and
total intravenous
anesthesia
(TIVA) on postoperative nausea
and vomiting

A prospective
randomized
control study
Sevoflurane
group
TIVA plus
ramosetron
group

72 women,
aged 20-60,
ASA status
I or II

Incidence and severity of
PONV, use of rescue antiemetics were recorded
during the first 24h after
surgery
Sevoflurane group
induced with 4-5mg/kg
thiopental sodium,
maintained with
sevoflurane in 50%
oxygen
TIVAR group 0.3 mg
ramsetron IV given prior
to induction with
remifentanil, propofol
All other medication was
universal in both groups
Post-operative
assessments made at 1h,
6h, 24h, incidence of
PONV, rescue anti-emetic
used

Thyroidectomy
under general
anesthesia

TIVAR Group
0-6h:
PONV: 4 (11.1%)
Rescue Antiemetic: 2 (5.6%)
6-24h:
PONV: 6 (16.7%)
Rescue Antiemetic: 3 (8.3%)
0-24h:
PONV: 7 (19.4%)
Rescue Antiemetic: 4 (11.1%)
Sevoflurane Group
0-6h:
PONV: 20 (55.6%)
Rescue Antiemetic: 11
(32.4%)
6-24h:
PONV:11 (30.6%)
Rescue Antiemetic: 6 (16.7%)
0-24h:
PONV: 22 (61.1%)
Rescue Antiemetic: 15
(41.7%)
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C-6: Kim, E., Park, H., Kang, H., Choi, J. & Lee, H. (2014). Antiemetic effect of propofol administered at the end of surgery in
laparoscopic assisted vaginal hysterectomy. The Korean Society of Anesthesiologists, 66(3): 210-215.
http://dx.doi.org/10.4097/kjae.2014.66.3.210
Aim/ Purpose
Design
Sample
Methods
Procedure
Results
To evaluate the
efficacy of
varying doses of
propofol given
15 minutes prior
to the end of
surgery

Prospective,
double-blind,
randomized
control study,
subjects randomly
placed into 3
groups (0.5 mg/kg
propofol, 1 mg/kg
propofol, and
saline group

107 women,
ASA physical
status I or II
presenting for
laparoscopyassisted
vaginal
hysterectomy
under general
anesthesia

Visual Analog Scale (VAS)
Incidence of PONV postoperative in time intervals
(0-2 hours, 2-24 hours, 24-48
hours)
Anesthesia induction and
maintenance was universal in
all cases

Laparoscopyassisted
vaginal
hysterectomy

0.5 mg/kg propofol,
1mg/kg propofol,
normal saline (control)
Incidence of nausea:
0-2 hours
Group 1: 4 (12%)
Group 2: 5 (15%)
Control: 16 (40%)
Incidence of vomiting:
0-2 hours
Group 1: 0
Group 2: 2 (6%)
Control: 3 (8%)
No significant effect in
2-24-hour, 24-48-hour
intervals related to
PCA use

42

C-7: Naghibi, K., Kashefi, P., Azamoush, H., & Zabihi, P. (2015). Prevention of postoperative nausea and vomiting with sub
hypnotic dose of propofol in patients undergoing lower abdominal surgery: A prospective, randomized, double-blind study.
Advanced Biomedical Research, 4(35). https://doi:10.4103/2277-9175.151239
Aim/ Purpose Design
Sample
Methods
Procedure
Medication Used/ Results
Compare the
efficacy of
sub hypnotic
dose of
propofol with
metocloprami
de

Prospective,
randomized, doubleblind, placebocontrolled study
Randomly assigned
into 1 of 4 groups:
propofol 20 mg,
propofol 30 mg,
metoclopramide 10
mg, placebo saline
group

104 subjects,
ASA physical
status I or II, aged
18-65 years, BMI
<30kg/m²
presenting for
elective lower
abdominal
surgery under
general anesthesia

Incidence and severity
of PONV, Side effects
of anti-emetics were
recorded during the
first 24 hours post
anesthesia (0-6h,612h, 12-24h),
duration of surgery
and recovery period
was collected
Baseline HR, SBP,
DBP, MAP, & SaO₂
was collected
Anesthesia induction
and maintenance was
universal in all cases

Elective lower Propofol 20 mg,
abdominal
Propofol 30 mg,
surgery
Metoclopramide 10mg, or
Saline given 15 minutes
prior to skin closure
Propofol 30 mg was
slightly more effective
than Metoclopramide 10
mg in the first 6 hours
post anesthesia
Both groups had 15.39%
N/V but propofol group
had lower mean dose of
rescue anti-emetic
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C-8: Yimer, H., Ayalew, N., Abdisa, Z. & Aregawi, A. (2017). Effect of sub-hypnotic dose of propofol on prevention of postoperative
nausea and vomiting as part of multimodal antiemetic in patients undergoing open abdominal surgery: A prospective cohort study.
International Journal of Surgery Open, 10(2018), 15-20. https://doi.org/10.1016/j.ijso.2017.11.008
Aim/Purpose
Design
Sample
Methods
Procedure
Medication Used/ Results
To assess the
efficacy of
sub-hypnotic
dose of
propofol on
incidence and
severity of
PONV after
having open
abdominal
surgery

Prospective
observational
cohort study
Two groups:
Propofol
Control
n=36/ group

72 subjects, >18
years old, ASA I
or II, subjects
presenting for
open abdominal
surgery under
general anesthesia

Incidence of PONV at
intervals of 0-6h, 6-12h,
12-24h, hemodynamic
parameters, respiratory
depression, severity of
nausea
Induction:
Ketamine 2 mg/kg or
thiopental sodium
5mg/kg, fentanyl
0.1mcg/kg
Intubation:
Suxamethonium
Maintenance:
vecuronium halothane
with or without morphine
Reversal:
neostigmine 0.05mg/kg
Atropine 0.01 mg/kg

Appendectomy,
resection and
anastomosis,
exploratory
laparotomy,
abdominal
hysterectomy,
cholecystectomy

Propofol
Reglan
Propofol group:
0-6h: 11 (30.6%)
6-12h: 8 (22.2%)
12-24h: 7 (19.4%)
Control group:
0-6h: 24 (66.7%)
6-12h: 14 (38.9%)
12-24h: 9 (25%)
No significant differences
in hemodynamic stability,
respiratory depression
Severity of nausea greater
in control group
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Appendix D
Results of Study
D-1: Abdelhamid, S. & Kamel, M. (2014). A prospective controlled study to assess the antiemetic effect of midazolam following
intragastric balloon insertion. Journal of Anesthesiology Clinical Pharmacology, 30(3), 383-386. https://doi:10.4103/09709185.137272
Nausea & Vomiting
Rescue AntiInduction/Maintenance Side Effects
Limitations
emetics
Meds
Incidence of N/V:
Level of sedation was measured
No control
Group 1: Ondansetron
No mention of Induction:
immediately post-operatively, 30- group was
only14 (56%)
rescue antifentanyl 1mcg/kg
minutes post, and 60 minutes post used in this
emetics in this propofol 2-2.5 mg/kg
study
Group 2: Ondansetron
study
cisatracurium 0.15mg/kg Group 1:Immediately Post:
& midazolam group:
4 (16%) awake, 20 (80%) mildly
No other
10 (34.5%)
Maintenance:
sedated, 1 (4%) moderately
side effects
Propofol 100mcg/kg/min sedated
were
Vomiting only:
based on total body
30 minutes post: 25 (100%)
mentioned
Group 1: 4 (16%)
weight
awake,0 mildly sedated
besides
Group 2: none
60 minutes post: 25 (100%) awake sedation
N/V score:
Group 1:11 (44%): no nausea,
Group2: Immediately Post:
no vomiting, 0 (0%): nausea
2 (6.9%) awake, 17 (58.6%)
only, 4 (16%): vomiting only, 10
mildly sedated
(40%): nausea and vomiting
10 (34.5%) moderately sedated
30 minutes post: 22 (75.9%)
Group 2: 19 (65.6%): no nausea,
awake,
no vomiting, 3 (10.3%): nausea
7 (24.1%) mildly sedated
only0 (0%): vomiting only, 7
60 minutes post: All subjects were
(24.1%): nausea and vomiting
awake
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D-2: Celik, M., Dostbil, A., Aksoy, M., Ince, I., Ahiskalioglu, A., Comez, M. & Fuat Erdem, A. (2014). Is infusion of sub
hypnotic propofol as effective as dexamethasone in prevention of post-operative nausea and vomiting related to laparoscopic
cholecystectomy? A randomized controlled trial. BioMed Research International, 2015, 15.https://dx.doi.org/10.1155/2015/349806
Nausea & Vomiting
Rescue Anti-emetics Induction/Maintenance Meds
Side Effects
Limitations
0-6 hours post:
Group C: 65%
Group P: 30%
Group D: 30%

0-6 hours post:
Group C: 13 (32.5%)
Group P: 4 (10%)
Group D: 4 (10%)

Induction: both groups
Thiopental sodium 5 mg/kg
Fentanyl 1 mcg/kg
Rocuronium

There was no significant
difference among the 3
groups regarding
delayed awakening

6-12 hours post:
Group C: 52.5%
Group P: 25%
Group D: 20%

6-12 hours post:
Group C: (20%)
Group P: (7.5%)
Group D: (2.5%)

Maintenance:
Group D:
1.0-2.5 % Sevoflurane with 50%
oxygen
Fentanyl 1 mcg/kg/h

Group C: 6.1 ± 1.2 min
Group P: 6.2 ± 1.21 min
Group D: 5.9 ± 1.24 min

12-24 hours post:
Group C: 45%
Group P: 20%
Group D: 10%

12-24 hours post:
No significant
differences among
all three groups

Group P: propofol 1mg/kg/h

Type of surgery
and length of
anesthesia times
were longer
than other
studies
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D-3: Heidari, S., Talakoub, R., & Yaraghi, Z. (2012). Comparing the preventive effect of midazolam and midazolamdexamethasone on postoperative nausea and vomiting in elective middle ear surgery. Advanced Biomedical Research, 1(9), 1-9.
http://doi:10.4103/2277-9175.96052
Nausea & Vomiting
Rescue Anti-emetics Induction/Maintenance Meds
Side Effects
Limitations
Mean nausea score
Midazolam group (M):
1.39 ±3.19
Midazolam/ Dexamethasone
group (M+D): 0.42 ±1.71
Mean Vomiting frequency:
PACU: 0.9 ± 0.29 (M), 0 ±0
(M+D)
6-12h: 1.09 ±2.41 (M)
0.3± 0.8 (M+D)
12-24h: 0.42± 1.32 (M),
0.03 ± 0.17

Rescue Antiemetic
M group:
12.9 ± 23.44
M+D group:
6.48 ± 9.54

Induction:
Fentanyl 2mcg/kg
Thiopental sodium 5 mg/kg
Atracurium 0.5 mg/kg
Maintenance:
Isoflurane 0.5-2%
Nitrous oxide 50% in Oxygen 50%
Morphine 0.1 mg/kg
Neuromuscular blocker reversal
Neostigmine 0.4 mg/kg
Atropine 0.02 mg/kg

Longer recovery
time in PACU in
midazolam group
due to more
vomiting episodes

Small sample
size, no
placebo or
control group
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D-4: Honarmand, A., Safavi, M., Khalili, G., & Mohammadnejad, F. (2012). Prophylactic administration of haloperidol plus
midazolam reduces postoperative nausea and vomiting better than using each drug alone in patients undergoing middle ear
surgery. Saudi Journal of Anesthesia, 6(2),145-151. https://doi:10.4103/1658-354X.97028
Nausea & Vomiting
Rescue Anti-emetics Induction/ Maintenance Meds Side Effects
Limitations
Haloperidol Group:
Complete Response 4 (20%)
0-2h: 6 (30%)
2-24h: 6 (30%)
0-24h: 12 (60%)
Midazolam Group:
Complete Response 9 (45%)
0-2h: 9 (45%)
2-24h: 4 (20%)
0-24h: 13 (65%)
Haloperidol/Midazolam
Group:
Complete Response 14
(70%)
0-2h: 3 (15%)
2-24h: 2 (10%)
0-24h: 5 (25%)
Control Group:
Complete Response 4 (20%)
0-2h: 10 (50%)
2-24h: 10 (50%)
0-24h: 20 (100%)

Rescue Anti-emetics:
ondansetron 4 mg IV
M Group: 2.0 ± 4.1
H Group: 2.5 ± 4.4
HM Group: 0.5 ± 1.5
C Group: 6.5 ±4.6
Time to first demand:
Group M: 3.4 ± 1.6 h
Group H: 2.3 ±2.2 h
Group HM: 12.1 ±
3.4 h
Group C: 0.4 ± 0.5 h

Induction:
Thiopental sodium 5 mg/kg
Fentanyl 3 mcg/kg
Atracurium 0.6 mg/kg

Group H:None
Group M: Headache: 2
Group HM: Headache: 2
Group C: Headache: 2

Maintenance:
Morphine 1 mg/kg PRN
Isoflurane 1.2%
Nitrous Oxide 50% in Oxygen

Sedation: minutes after
arrival to PACU
5 min: 3 in each group
15 min: 2.5 in H group, 2
in Group M, HM, C
30 min: 1 in Group H,
HM, C, 1.5 in Group M
60 min: 1 in Group H, 2
in Group M, HM, C
120 min: 1 in each group

Neuromuscular blockade
Reversed:
Neostigmine 0.04 mg/kg
Atropine 0.02 mg/kg

No significant difference
in VAS scores and postoperative analgesic
requirement

Small
sample size,
the severity
of nausea
was not
evaluated
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D-5: Joe, H. B., Lee, S. Y., Kim, J.-S., Chang, H. S., Jeong, Y., Jeong, H., & Park, S. Y. (2016). Effect of total intravenous
anesthesia and prophylactic ramosetron on postoperative nausea and vomiting after thyroidectomy: A prospective, randomized
controlled study. Journal of International Medical Research, 44(1), 81–88. https://doi.org/10.1177/0300060515607384
Nausea & Vomiting
Rescue Anti-emetics
Induction/Maintenance Meds
Side Effects
Limitations
TIVAR Group
0-6h:
4 (11.1%)
6-24h:
6 (16.7%)
0-24h:
7 (19.4%)
Sevoflurane Group
0-6h:
20 (55.6%)
6-24h:
11 (30.6%)
0-24h:
22 (61.1%)

TIVAR Group:
0-6h: 2 (5.6%)
6-24h: 3 (8.3%)
0-24h: 4 ( 11.1%)
Sevoflurane Group:
0-6h: 11 (32.4%)
6-24h: 6 (16.7%)
0-24h: 15 (41.7%)

Sevoflurane Group:
Thiopental sodium 4-5 mg/kg
Sevoflurane in 50% oxygen

TIVAR group:
Headache: 16 (44.4%)
Dizziness: 4 (11.1%)

TIVAR Group:
Sevoflurane Group:
Ramosetron 0.3 mg prior to
Headache: 15 (41.7%)
induction
Dizziness: 10 (27.8%)
Propofol: induced/maintained (target
blood concentration 3.0-4.5mcg/ml)
Remifentanil: induced/ maintained
(target blood concentration 3.5-4.5
ng/ml)
Paralytic, reversal, pain med same
for both groups: rocuronium 0.6
m/kg
Pyridostigmine 0.03 mg/kg
Glycopyrrolate 0.002 mg/kg
Ketorolac 30mg

Lack of TIVA
control group
(not receiving
ramosetron)
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D-6: Kim, E., Park, H., Kang, H., Choi, J. & Lee, H. (2014). Antiemetic effect of propofol administered at the end of surgery in
laparoscopic assisted vaginal hysterectomy. The Korean Society of Anesthesiologists, 66(3): 210-215.
http://dx.doi.org/10.4097/kjae.2014.66.3.210
Nausea & Vomiting
Rescue Anti-emetics Induction/Maintenance Meds Side Effects
Limitations
Control Group (n=40)
0-2h: 19 (47.5%)
2-24h: 8 (20%)
24-48h: 2 (5%)

Control Group
0-2h: 9 (22.5%)
2-24h: 2 (5%)
24-48h: 0

Propofol 0.5 Group
(n=33)
0-2h: 4 (12.1%)
2-24h: 10 (30.3%)
24-48h: 3 (7.5%)

Propofol 0.5 Group
0-2h: 1 (3%)
2-24h: 6 (18.1%)
24-48h: 4 (11.7%)

Propofol 1.0 Group
(n=34)
0-2h: 7 (20.6%)
2-24h: 13 (38.2%)
24-48h: 3 (8.8%)

Propofol 1.0 Group
0-2h: 2 (5.9%)
2-24h: 7 (20.5%)
24-48h: 3 (8.8%)

Pre-operative:
Diazepam 7mg Orally
Induction:
Propofol 2mg/kg
Rocuronium 0.8mg/kg
Maintenance:
Sevoflurane 1-3%
Nitrous Oxide 50% in
Oxygen

Delayed emergence time:
Control Group:
11.2 ± 3.8 minutes
Propofol 0.5 Group:
13.8 ± 5.1 minutes
Propofol 1.0 Group:
14.6 ± 6.5 minutes
VAS Score: Post-operative
pain and severity of nausea
VAS >5, Vomiting >1, need
for rescue anti-emetic in
PACU
Control Group:
0-2h: 6.7 ± 1.8, 2-24h: 5.3 ±
1.6, 24-48h: 1.6 ± 0.9
Propofol 0.5 Group:
0-2h: 6.4 ± 2.9, 2-24h: 4.9 ±
2.1, 24-48h: 1.5 ± 1.2
Propofol 1.0 Group:
0-2h: 6.2 ± 2.9, 2-24h: 5.1 ±
1.7, 24-48h: 1.8 ± 1.4

Relatively small
sample size, no
comparison
between
propofol and
other antiemetics
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D-7: Naghibi, K., Kashefi, P., Azamoush, H., & Zabihi, P. (2015). Prevention of postoperative nausea and vomiting with sub
hypnotic dose of propofol in patients undergoing lower abdominal surgery: A prospective, randomized, double-blind study.
Advanced Biomedical Research, 4(35). https://doi:10.4103/2277-9175.151239
Nausea & Vomiting
Rescue Anti-emetics
Induction/ Maintenance Meds
Side Effects
Limitations
Control Group:
8 (30.8%)
Propofol 20mg Group:
6 (23.1%)
Propofol 30mg Group:
4 (15.2%)
Metoclopramide 10mg
Group
4 (15.2%)

Metoclopramide
0.15mg/kg IV used
Control Group:
6 (23.1%), Mean dose:
12 ± 4.6mg
Propofol Group (G1):
4 (15.2%), Mean dose:
5.2 ± 2.1 mg

(n=26 all groups)
Propofol Group (G2):
2 (7.8%),Mean dose: 5
± 0.9mg
Metoclopramide
Group:
2 (7.8%), Mean dose: 6
± 1.8mg

Induction:
Sodium thiopental 6mg/kg
Fentanyl 2mg/kg
Morphine 0.15mg/kg
Atracurium 0.6mg/kg
Maintenance:
Isoflurane 1 MAC
50% Nitrous Oxide & Oxygen

No side effects from
the anti-emetics
were noted in any
group (headache,
dizziness,
drowsiness),
No other side effects
noted in the study

Small sample size,
followed subjects
for only 24 hours
post-operatively
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D-8: Yimer, H., Ayalew, N., Abdisa, Z. & Aregawi, A. (2017). Effect of sub-hypnotic dose of propofol on prevention of
postoperative nausea and vomiting as part of multimodal antiemetic in patients undergoing open abdominal surgery: A prospective
cohort study. International Journal of Surgery Open, 10(2018), 15-20. https://doi.org/10.1016/j.ijso.2017.11.008
Nausea & Vomiting
Rescue Anti-emetics
Induction/Maintenance Meds
Side Effects
Limitations
Propofol group:
0-6h: 11 (30.6%)
6-12h: 8 (22.2%)
12-24h: 7 (19.4%)
Control group:
0-6h: 24 (66.7%)
6-12h: 14 (38.9%)
12-24h: 9 (25%)

Reglan 10mg for
severe nausea (>3
episodes)

Induction:
Ketamine 2 mg/kg or thiopental
sodium 5mg/kg, fentanyl 0.1mcg/kg

Propofol Group:
0-6h: 5 (13.9%)
6-12h: 2 (5.6%)
12-24h: 0

Intubation: Suxamethonium
Maintenance: vecuronium halothane
with or without morphine

Control Group:
0-6h: 15 (41.7%)
6-12h: 5 (13.9%)
12-24h: 1 (2.8%)

Reversal:
neostigmine 0.05mg/kg
Atropine 0.01 mg/kg

Shivering:
Propofol: 6 (16.7%)
Control: 5 (13.9%)

Lack of
randomization,
total antiemetic
consumption
not reported
after 6h,
followed
subjects for
24h
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Appendix E
Critical Appraisal Skills Programme (CASP) Checklist
Section A:

Are the results of the review valid?

Yes

Can’t Tell

No

1. Did the review address a clearly focused question?
2. Did the authors look for the right type of papers?
3. Do you think all the important, relevant studies
were included?
4. Did the review’s authors do enough to assess quality
of the included studies?
5. If the results of the review have been combined,
was it reasonable to do so?
Section B: What are the results?
6. What are the overall results of the review?
7. How precise are the results?
Section C: Will the results help locally?

Yes

Can’t Tell

No

8. Can the results be applied to the local population?
9. Were all important outcomes considered?
10. Are the benefits worth the harms and costs?

Critical Appraisal Skills Programme (2018). CASP checklist.. Retrieved from https://casp-uk.net/ca
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Appendix F
Completed CASP Checklist
F-1: Abdelhamid, S. & Kamel, M. (2014). A prospective controlled study to assess the
antiemetic effect of midazolam following intragastric balloon insertion. Journal of
Anesthesiology Clinical Pharmacology, 30(3), 383-386. https://doi:10.4103/09709185.137272
Section A: Are the results of the trial valid?
YES
CAN’T
NO
TELL
1. Did the trial address a clearly focused issue?
X
2. Was the assignment of patients to treatments
randomized?

X

3. Were all the patients who entered the trial
properly accounted for at its conclusion?

X

4. Were patients, health workers, and study
personnel “blind” to treatment?

X

5. Were the groups similar at the start of the
trial?

X

6. Aside from the experimental intervention,
were the groups treated equally?

X

Section B: What are the results?
7. How large was the treatment effect?

54 Subjects

8. How precise was the estimate of the
treatment effect?

Significant
reduction in
PONV in combo
group

Section C: Will the results help locally?
9. Can the results be applied in your context?

X

10. Were all clinically important outcomes
considered?

X

11. Are the benefits worth the harms and costs?

X
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F-2: Celik, M., Dostbil, A., Aksoy, M., Ince, I., Ahiskalioglu, A., Comez, M. & Fuat
Erdem, A. (2014). Is infusion of sub hypnotic propofol as effective as dexamethasone in
prevention of post-operative nausea and vomiting related to laparoscopic
cholecystectomy? A randomized controlled trial. BioMed Research International, 2015,
1-5.https://dx.doi.org/10.1155
Section A: Are the results of the trial valid?

YES

1. Did the trial address a clearly focused
issue?

X

2. Was the assignment of patients to
treatment randomized?

X

3. Were all the patients who entered the trial
properly accounted for at its conclusion?

X

4. Were patients, health workers, and study
personnel “blind” to treatment?

X

5. Were the groups similar at the start of the
trial?

X

6. Aside from the experimental intervention,
were the groups treated equally?

X

Section B: What are the results?
7. How large was the treatment effect?

120 subjects

8. How precise was the estimate of the
treatment effect?

Propofol &
Dexamethasone
comparable

Section C: Will the results help locally?
9. Can the results be applied in your
context?

X

10. Were all clinically important outcomes
considered?

X

11. Are the benefits worth the harms and costs?

X

CAN’T
TELL

NO
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F-3: Heidari, S., Talakoub, R., & Yaraghi, Z. (2012). Comparing the preventive effect
of midazolam and midazolam-dexamethasone on postoperative nausea and vomiting
in elective middle ear surgery. Advanced Biomedical Research, 1(9), 1-9.
http://doi:10.4103/2277-9175.96052
Section A: Are the results of the trial valid?
YES
CAN’T
NO
TELL
1. Did the trial address a clearly focused
X
issue?
2. Was the assignment of patients to treatment
randomized?

X

3. Were all the patients who entered the trial
properly accounted for at its conclusion?

X

4. Were patients, health workers, and study
personnel “blind” to treatment?

X

5. Were the groups similar at the start of the
trial?

X

6. Aside from the experimental intervention,
were the groups treated equally?

X

Section B: What are the results?
7. How large was the treatment effect?

66 subjects

8. How precise was the estimate of the
treatment effect?

Reduced
vomiting
frequency &
less rescue
antiemetic in
combo group

Section C: Will the results help locally?
9. Can the results be applied in your context?

X

10. Were all clinically important outcomes
considered?

X

11. Are the benefits worth the harms and
costs?

X
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F-4: Honarmand, A., Safavi, M., Khalili, G., & Mohammadnejad, F. (2012). Prophylactic
administration of haloperidol plus midazolam reduces postoperative nausea and vomiting
better than using each drug alone in patients undergoing middle ear surgery. Saudi Journal
of Anesthesia, 6(2),145-151. https://doi:10.4103/1658-354X.97028
Section A: Are the results of the trial valid?
YES
CAN’T
NO
TELL
1. Did the trial address a clearly focused issue?
X
2. Was the assignment of patients to treatments
randomized?

X

3. Were all the patients who entered the trial
properly accounted for at its conclusion?

X

4. Were patients, health workers, and study
personnel “blind” to treatment?

X

5. Were the groups similar at the start of the
trial?

X

6. Aside from the experimental intervention,
were the groups treated equally?

X

Section B: What are the results?
7. How large was the treatment effect?

80 subjects

8. How precise was the estimate of the
treatment effect?

Midazolam alone
reduced PONV
more than Haldol
alone, but combo
was more effective
than individual
meds

Section C: Will the results help locally?
9. Can the results be applied in your context?

X

10. Were all clinically important outcomes
considered?

X

11. Are the benefits worth the harms and costs?

X
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F-5: Joe, H. B., Lee, S. Y., Kim, J.-S., Chang, H. S., Jeong, Y., Jeong, H., & Park, S.
Y. (2016). Effect of total intravenous anesthesia and prophylactic ramosetron on
postoperative nausea and vomiting after thyroidectomy: A prospective, randomized
controlled study. Journal of International Medical Research, 44(1), 81–88.
https://doi.org/10.1177/0300060515607384
Section A: Are the results of the trial valid?
YES
CAN’T
NO
TELL
1. Did the trial address a clearly focused issue?
X
2. Was the assignment of patients to treatments
randomized?

X

3. Were all the patients who entered the trial
properly accounted for at its conclusion?

X

4. Were patients, health workers, and study
personnel “blind” to treatment?

X

5. Were the groups similar at the start of the
trial?

X

6. Aside from the experimental intervention,
were the groups treated equally?

X

Section B: What are the results?
7. How large was the treatment effect?

72 subjects

8. How precise was the estimate of the
treatment effect?

Significant
reduction of
PONV in
propofol group

Section C: Will the results help locally?
9. Can the results be applied in your context?

X

10. Were all clinically important outcomes
considered?

X

11. Are the benefits worth the harms and costs?

X
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F-6: Kim, E., Park, H., Kang, H., Choi, J. & Lee, H. (2014). Antiemetic effect of propofol
administered at the end of surgery in laparoscopic assisted vaginal hysterectomy. The
Korean Society of Anesthesiologists, 66(3): 210-215.
http://dx.doi.org/10.4097/kjae.2014.66.3.210
Section A: Are the results of the trial valid?
YES
CAN’T NO
TELL
1. Did the trial address a clearly focused issue?
X
2. Was the assignment of patients to treatments
randomized?

X

3. Were all the patients who entered the trial
properly accounted for at its conclusion?

X

4. Were patients, health workers, and study
personnel “blind” to treatment?

X

5. Were the groups similar at the start of the trial?

X

6. Aside from the experimental intervention,
were the groups treated equally?

X

Section B: What are the results?
7. How large was the treatment effect?

107 subjects

8. How precise was the estimate of the
treatment effect?

Significant
reduction in
PONV compared
to control group

Section C: Will the results help locally?
9. Can the results be applied in your context?

X

10. Were all clinically important outcomes
considered?

X

11. Are the benefits worth the harms and costs?

X
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F-7: Naghibi, K., Kashefi, P., Azamoush, H., & Zabihi, P. (2015). Prevention of
postoperative nausea and vomiting with sub hypnotic dose of propofol in patients
undergoing lower abdominal surgery: A prospective, randomized, double-blind study.
Advanced Biomedical Research, 4(35). https://doi:10.4103/2277-9175.151239
Section A: Are the results of the trial valid?
YES
CAN’T NO
TELL
1. Did the trial address a clearly focused issue?
X
2. Was the assignment of patients to treatments
randomized?

X

3. Were all the patients who entered the trial
properly accounted for at its conclusion?

X

4. Were patients, health workers, and study
personnel “blind” to treatment?

X

5. Were the groups similar at the start of the
trial?

X

6. Aside from the experimental intervention,
were the groups treated equally?

X

Section B: What are the results?
7. How large was the treatment effect?

104 subjects

8. How precise was the estimate of the
treatment effect?

Propofol groups
required less rescue
antiemetics

Section C: Will the results help locally?
9. Can the results be applied in your context?

X

10. Were all clinically important outcomes
considered?

X

11. Are the benefits worth the harms and costs?

X
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F-8: Yimer, H., Ayalew, N., Abdisa, Z. & Aregawi, A. (2017). Effect of sub-hypnotic
dose of propofol on prevention of postoperative nausea and vomiting as part of
multimodal antiemetic in patients undergoing open abdominal surgery: A prospective
cohort study. International Journal of Surgery Open, 10(2018), 15-20.
https://doi.org/10.1016/j.ijso.2017.11.008
Section A: Are the results of the trial valid?
YES
CAN’T
NO
TELL
1. Did the trial address a clearly focused
X
issue?
2. Was the assignment of patients to
treatments randomized?

X

3. Were all the patients who entered the trial
properly accounted for at its conclusion?

X

4. Were patients, health workers, and study
personnel “blind” to treatment?

X

5. Were the groups similar at the start of the
trial?

X

6. Aside from the experimental intervention,
were the groups treated equally?

X

Section B: What are the results?
7. How large was the treatment effect?
8. How precise was the estimate of the
treatment effect?

72 Subjects
Propofol group less
incidence of PONV
& less rescue antiemetic for severe
nausea

Section C: Will the results help locally?
9. Can the results be applied in your context?
X
10. Were all clinically important outcomes
considered?

X

11. Are the benefits worth the harms and
costs?

X
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Appendix G
Cross-study Analysis
Study
#

Nausea & Vomiting

1

Significant reduction in severity of
PONV in ondansetron/ midazolam
group using N/V scores, No
significant reduction of incidence of
PONV

2

Significant reduction in PONV in
propofol and dexamethasone group
compared to control, Group D & P
comparable

3

Reduced mean nausea score &
reduced vomiting frequency in
midazolam/ dexamethasone group
Midazolam alone reduced PONV
more than Haldol alone,
Haldol/midazolam group more
effective

4

Significant reduction in propofol
group

Rescue Anti-emetics

Adverse Effects

Opioid Use

No mention of rescue antiemetics in the study

Significant mild sedation in both
groups, significant moderate
sedation in G2

Fentanyl for
induction

0-6h: Group D & P comparable,
both reduced compared to
control
6-12h: Group D superior to
Group P
12-24h: no significant
differences among groups

No significant difference in
delayed emergence among all
groups

Fentanyl for
induction &
maintenance
for group D

Less rescue anti-emetic in
midazolam/dexamethasone
group

Longer recovery times in PACU
Fentanyl for
related to more vomiting episodes induction &
in midazolam group
morphine
during in
both groups

No significant adverse effects in
all groups

Fentanyl at
induction,
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5

Significant reduction in propofol
groups compared to control

6

Reduced PONV in propofol groups
compared to control, Propofol 30mg
comparable to metoclopramide
group

Midazolam group(M) required
less than Haldol group (H), MH
group required less than M
group
Significant reduction in PONV
in propofol group compared to
sevoflurane group
Significantly less in both
propofol groups compared to
control in 0-2h interval

7
Significant reduction in PONV in
propofol group compared to control
group
8
Significant reduction in PONV in
propofol group compared to control
group

Significant less requirement for
Group 1,2,& 3 compared to
control

Significant less requirement for
propofol group compared to
control group

No significant adverse effects
between groups

morphine
PRN in all
groups
Remifentanil
in TIVAR
group

Time to extubation significantly
longer than control but PACU
stay unaffected
Fentanyl
PCA end
of case
No significant adverse effects
noted

No significant adverse effects
noted

Fentanyl at
induction
Morphine
Fentanyl at
induction
Morphine
for
intubation

29

